Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Trademark and unfair competition matters for Diageo North America
Represents Diageo North America in a variety of trademark and unfair competition matters, including litigation in federal district court and before more
Restructuring of aerospace and rail transportation company
Represented an aerospace and rail transportation company in its restructuring of parts of its Swedish operations. The matter involved labor law more
Economic incentive package for major specialty home furnishings company
Represented a major retailer in the specialty home furnishings business in obtaining an economic incentive package for an in-sourcing manufacturing more
Hodges v. MedAssets Net Revenue Systems LLC
Served as lead counsel to MedAssets, Inc. and one of its subsidiaries, which were sued for alleged breach of an earn-out agreement. Plaintiff alleged more